Natera, Inc. products

Oncology Test

Model Signatera - Transforming the Management of Cancer with Personalized Testing

Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for cancer management.

Natera - Altera Tumor Profiling

Support treatment decisions with comprehensive tumor profiling. Gain deep insight into the tumor’s genomic alterations and oncology biomarkers with Altera. The detailed sequencing report includes FDA-approved treatments, novel treatment approaches and ongoing clinical trials targeting found mutations. Unlike any other tumor profiling assay, Altera also enables molecular residual disease (MRD) monitoring with the Signatera assay.

Organ Health Test

Model Prospera - Kidney Transplant Assessment

Covered by Medicare, Prospera is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney. Through the use of advanced cell-free DNA technology, Prospera increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.

Kidney Gene Panel

Renasight is a test to determine if there is a genetic cause for an individual’s kidney disease or if there is an increased hereditary risk due to family history. The test uses a blood or saliva sample to test 385 genes associated with chronic kidney disease (CKD). Results are available in approximately 3 weeks.

Women’s Health Test

Model Horizon - Comprehensive, Actionable Carrier Screening

Horizon carrier screening helps couples determine the risk of passing on serious genetic conditions to their child. It can be performed either preconception (ideally) or during pregnancy.

Tests

Panorama - Noninvasive Prenatal Testing (NIPT)

Panorama is a blood-based genetic, prenatal screening test of the pregnant person that screens for common chromosomal conditions that affect a baby’s health. Panorama uses SNP*-based technology to deliver highly accurate results and unique insights for both singleton and twin pregnancies. Panorama can be performed as early as nine weeks gestation. Most results will be returned to your doctor within 5-7 calendar days.

Empower - Hereditary Cancer Testing, Made Accessible

Empower is a genetic test for those who want to know more about their risk of developing cancer, why it might be common in their family, or want to inform treatment options following a cancer diagnosis. Empower screens for genes associated with increased risk for common hereditary cancers. Our Empower multi-cancer panels include commonly screened-for genes associated with 12+ types of cancer.

Vistara - Single-Gene NIPT

Vistara is the most comprehensive prenatal single-gene screening test for serious genetic conditions. These conditions, which affect quality of life, could benefit from early intervention and might otherwise go undetected. Vistara tests for 25 serious genetic conditions with a blood draw from the mother. Most results will be returned to a clinician within 2-3 weeks.